{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T23:10:29Z","timestamp":1699830629550},"reference-count":10,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,19]],"date-time":"2006-07-19T00:00:00Z","timestamp":1153267200000},"content-version":"vor","delay-in-days":8661,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[1982,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Seventy\u2010five patients accepted postmastectomy adjuvant CMF chemotherapy for stage II and III carcinoma of the breast. All patients, irrespective of age, were started on the same drug dosages. About 42% of the patients had leukopenia during the first two cycles; this rate was similar for patients who dropped out of the program early and those who stayed on for six or more months. Patients who developed leukopenia early are more likely to receive less than 65% of mean total CMF dosages (MTD). Otherwise, 30% of patients that never had leukopenia or had leukopenia that appeared late received more than 85% of the prescribed CMF. In our series, postmenopausal patients did not have more problem with leukopenia than premenopausal patients (thrombocytopenia occurred rarely in both groups). Among the 58 patients who had CMF for 6 months or longer, 79% had less than 85% MTD of CMF. The dosages had to be reduced for drug\u2010related and other reasons, and leukopenia only accounted for 22% of patients who had reduced CMF dosages.<\/jats:p>","DOI":"10.1002\/jso.2930210303","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T08:01:04Z","timestamp":1171958464000},"page":"149-154","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant chemotherapy (CMF) for breast carcinoma: Hematological side effects"],"prefix":"10.1002","volume":"21","author":[{"given":"Yeu\u2010tsu N.(Margaret)","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,19]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197602192940801"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197611)38:5<1882::AID-CNCR2820380503>3.0.CO;2-H"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197706)39:6<2904::AID-CNCR2820390677>3.0.CO;2-8"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198101013040103"},{"key":"e_1_2_1_6_2","unstructured":"Lee Y\u2010TN:Adjuvant chemotherapy (CMF) for breast carcinoma: Patient's compliance and total dose achieved. Am J Clin Oncol (in press)."},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197905)43:5<1613::AID-CNCR2820430508>3.0.CO;2-8"},{"key":"e_1_2_1_8_2","first-page":"369","article-title":"Are the elderly predisposed to toxicity from cancer chemotherapy?","volume":"3","author":"Begg CB","year":"1980","journal-title":"Cancer Clin Trials"},{"key":"e_1_2_1_9_2","first-page":"363","article-title":"Acute toxicity during adjuvant chemotherapy for breast cancer: The National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents","volume":"65","author":"Glass A","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(77)90194-5"},{"key":"e_1_2_1_11_2","first-page":"443","article-title":"The importance of leukopenia in breast cancer adjuvant therapy with melphalan (MPL)","volume":"22","author":"Carpenter JT","year":"1981","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.2930210303","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.2930210303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T22:54:35Z","timestamp":1699829675000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.2930210303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,11]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1982,11]]}},"alternative-id":["10.1002\/jso.2930210303"],"URL":"https:\/\/doi.org\/10.1002\/jso.2930210303","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,11]]}}}